[Skip to Content]

Clinical Trials for Cancer Treatment

Cancer TypePrincipal InvestigatorKeyword OR
ClinicalTrials.Gov ID
 

You searched for Keyword (immunotherapy): 10 trials found.

Click sort in the column header to sort records.
Study TitlePI
2215-CL-0201: A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Read more
Teresa C Gentile, MD, PhD
A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY
Read more
Gennady Bratslavsky, MD
A031501-Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Read more
Alina Basnet
EA5142 - Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Read more
Stephen L Graziano, MD
EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature driven Analysis
Read more
Stephen L Graziano, MD
NRG-HN004 - Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
Read more
Seung Shin Hahn, MD
NRG-LU005 - LIMITED STAGE SMALL CELL LUNG CANCER (LS-SCLC): A PHASE II/III RANDOMIZED STUDY OF CHEMORADIATION VERSUS CHEMORADIATION PLUS ATEZOLIZUMAB
Read more
Stephen L Graziano, MD
S1418 - A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes after Neoadjuvant Chemotherapy
Read more
Abirami Sivapiragasam
S1801 - A Phase II Randomized Study Of Adjuvant Versus Neoadjuvant Mk-3475 (Pembrolizumab) For Clinically Detectable Stage Iii-Iv High Risk Melanoma
Read more
Abirami Sivapiragasam
UTX-TGR-205 - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma
Read more
Teresa C Gentile, MD, PhD

Search Again

Top